Is Century Therapeutics, Inc. (IPSC) a Buy, Sell, or Hold?
NASDAQ : IPSC
Century Therapeutics, Inc.
$2.25 USD
-$0.01 (-0.44%)
- Volume
- 1.1M
- Average Volume
- 1.28M
- Market Capitalization
- $194.78M
- P/E Ratio
- -1.80
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.04
- Year Low
- $0.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.25
Company Overview
NASDAQ
Brent Pfeiffenberger
Biotechnology
Healthcare
IPSC
78
US
USD
Liquidity Metrics
0.18
10.25
10.25
3.76
0.00
Sales & Valuation
$109.16M
0.00
0.74
-2.03
-1.11
Profitability
-$0.11
-$9.58M
0.00%
0.00%
-53.23%
-33.01%
P/E Metrics
-1.80
0.00
0.00
Analyst Price Target & Rating
$3.00
$4.00
$2.00
2/5
9 Analysts
-25.00%
Poll Results
About Century Therapeutics, Inc. (NASDAQ:IPSC) Stock
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A mult ... i-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
2026-07-09 08:00:00
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:
2026-06-08 16:05:00
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0, in an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, Louisiana.
2026-06-08 16:05:00
Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models Allo-Evasion 5. 0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression Phase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet cell content CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027 PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc.
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
2026-05-14 08:00:00
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors.
Century Therapeutics Reports First Quarter Financial Results and Business Updates
2026-05-13 08:00:00
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.
2026-04-30 16:05:00
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
2026-04-24 07:22:01
Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813 for Type 1 diabetes, now the pipeline's main value driver. Recent management actions reduced quarterly cash burn from $35M to $20M, extending runway to Q1 2028 after a 134% dilutive PIPE.
Frequently Asked Questions
-
What is the current Century Therapeutics, Inc. (IPSC) stock price?
-
Century Therapeutics, Inc.(NASDAQ:IPSC) stock price is $2.25 in the last trading session. During the trading session, IPSC stock reached the peak price of $3.04 while $0.435 was the lowest point it dropped to. The percentage change in IPSC stock occurred in the recent session was --0.44% while the dollar amount for the price change in IPSC stock was -$0.01.
-
IPSC's industry and sector of operation?
-
The NASDAQ listed IPSC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IPSC?
-
Chad A. Cowan | Chief Scientific Officer
Krista Kauppinen | VP, General Counsel & Head of Intellectual Property
Michael Naso | Senior Vice President of Cell Engineering
Megan Bilson | Chief People Officer
Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary -
How many employees does IPSC have?
-
Number of IPSC employees currently stands at 78. IPSC operates from 3675 Market Street, Philadelphia, PA 19104, US.
-
Link for IPSC official website?
-
Official Website of IPSC is: https://www.centurytx.com
-
How do I contact IPSC?
-
IPSC could be contacted at phone #267 817 5790 and can also be accessed through its website. IPSC operates from 3675 Market Street, Philadelphia, PA 19104, US.
-
How many shares of IPSC are traded daily?
-
The average number of IPSC shares traded daily for last 3 months was 1.28M.
-
What is the market cap of IPSC currently?
-
The market value of IPSC currently stands at $194.78M with its latest stock price at $2.25